Compare Ascendis Pharma A/S (ASND) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Hims and Hers Health Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Hims and Hers Health Inc trades at $34.04 (market cap $7.96B). The key difference: Ascendis Pharma A/S is far larger — about 2.2× Hims and Hers Health Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| ASND | HIMS | |
|---|---|---|
Market Cap | $17.74B | $7.96B |
Sector | Health | Health |
52-Week High | $277.18 | $66.18 |
52-Week Low | $163.32 | $14.52 |
Enterprise Value | $18.11B | $8.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Hims & Hers Health trades at $34.38, down 3.02% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights expansion in weight-loss therapies and a $400 million JPMorgan facility for financial flexibility, as the stock recovers from earlier regulatory concerns.
The outlook is cautiously optimistic, driven by growth in GLP-1 products and international expansion, but high valuation ratios and projected 2026 losses pose risks. Analyst consensus is a 'Hold' with a $33.57 price target, suggesting limited near-term upside from current levels amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
